Colapietro, F; Maisonneuve, P; Lytvyak, E; Beuers, U; Verdonk, RC; van der Meer, AJ; van Hoek, B; ... Purnak, T; + view all Colapietro, F; Maisonneuve, P; Lytvyak, E; Beuers, U; Verdonk, RC; van der Meer, AJ; van Hoek, B; Kuiken, SD; Brouwer, JT; Muratori, P; Aghemo, A; Carella, F; van den Berg, AP; Zachou, K; Dalekos, GN; Di Zeo-Sánchez, DE; Robles, M; Andrade, RJ; Montano-Loza, AJ; van den Brand, FF; Slooter, CD; Macedo, G; Liberal, R; de Boer, YS; Lleo, A; van Gerven, N; van Erpecum, K; Ouden, JD; Brouwer, J; Vrolijk, J; Gevers, T; Drenth, J; Guichelaar, M; Bouma, G; Schreuder, TCMA; van der Wouden, EJ; Baak, LC; Stadhouders, P; Klemt-Kropp, M; Verhagen, M; Bhalla, A; Kuijvenhoven, J; Almasio, P; Alvarez, F; Andrade, R; Arikan, C; Assis, D; Bardou-Jacquet, E; Biewenga, M; Cancado, E; Cazzagon, N; Chazouillères, O; Colloredo, G; Cuarterolo, M; Dalekos, G; Debray, D; Robles-Díaz, M; Dyson, J; Efe, C; Engel, B; Ferri, S; Fontana, R; Gatselis, N; Gerussi, A; Halilbasic, E; Halliday, N; Heneghan, M; Hirschfield, G; van Hoek, B; Hørby Jørgensen, M; Indolfini, G; Iorio, R; Invernizzi, P; Jeong, S; Jones, D; Kelly, D; Kerkar, N; Lacaille, F; Lammert, C; Leggett, B; Lenzi, M; Levy, C; Liberal, R; Lleo, A; Lohse, A; Lopez, SI; de Martin, E; McLin, V; Mieli-Vergani, G; Milkiewicz, P; Mohan, N; Muratori, L; Nebbia, G; van Nieuwkerk, C; Oo, Y; Ortega, A; Páres, A; Pop, T; Pratt, D; Purnak, T; - view fewer (2024) Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis. Journal of Hepatology , 80 (1) pp. 53-61. 10.1016/j.jhep.2023.09.010.

Text IncidencePredictorsofHCCinAIHpatientsJHepatol2023.pdf - Accepted Version Access restricted to UCL open access staff until 5 January 2025. Download (7MB)

Abstract

BACKGROUND AND AIMS: Autoimmune hepatitis (AIH) is a rare chronic liver disease of unknown aetiology; the risk of hepatocellular carcinoma (HCC) remains unclear and risk factors are not well-defined. We aimed to investigate the risk of HCC across a multicentre AIH cohort and to identify predictive factors. METHODS: We performed a retrospective, observational, multicentric study of patients included in the International Autoimmune Hepatitis Group Retrospective Registry. The assessed clinical outcomes were HCC development, liver transplantation, and death. Fine and Gray regression analysis stratified by centre was applied to determine the effects of individual covariates; the cumulative incidence of HCC was estimated using the competing risk method with death as a competing risk. RESULTS: A total of 1,428 patients diagnosed with AIH from 1980 to 2020 from 22 eligible centres across Europe and Canada were included, with a median follow-up of 11.1 years (interquartile range 5.2-15.9). Two hundred and ninety-three (20.5%) patients had cirrhosis at diagnosis. During follow-up, 24 patients developed HCC (1.7%), an incidence rate of 1.44 cases/1,000 patient-years; the cumulative incidence of HCC increased over time (0.6% at 5 years, 0.9% at 10 years, 2.7% at 20 years, and 6.6% at 30 years of follow-up). Patients who developed cirrhosis during follow-up had a significantly higher incidence of HCC. The cumulative incidence of HCC was 2.6%, 4.6%, 5.6% and 6.6% at 5, 10, 15, and 20 years after the development of cirrhosis, respectively. Obesity (hazard ratio [HR] 2.94, p = 0.04), cirrhosis (HR 3.17, p = 0.01), and AIH/PSC variant syndrome (HR 5.18, p = 0.007) at baseline were independent risk factors for HCC development. CONCLUSIONS: HCC incidence in AIH is low even after cirrhosis development and is associated with risk factors including obesity, cirrhosis, and AIH/PSC variant syndrome.

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as CSVJSONXML

Downloads by country - last 12 months

Export as XMLJSONCSV

Archive Staff Only

View Item